XFOR EBITDA | X4 PHARMACEUTICALS, INC

X4 PHARMACEUTICALS, INC (XFOR) EBITDA

2026-06-30: Basis Reported; EBITDA -$15.39M*; Operating income -$16.39M; Depreciation and amortization $997.00K*.
2026-03-31: Basis Reported; EBITDA -$20.08M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$23.48M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$27.29M*; Operating income -$27.51M; Depreciation and amortization $223.00K*.

Complete source-backed ebitda history.

Available history: 2016-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$15.39M*	-$16.39M	$997.00K*	$8.81M	-174.81%*	(m)	-$20.79M*	(m)	$15.08M	(m)	$2.00K
2026-03-31	Reported	-$20.08M	(m)	(m)	(m)	-741.62%	(m)	-$19.60M	(m)	$15.45M	(m)	$0.00
2025-12-31	Reported	-$23.48M	(m)	(m)	(m)	-914.17%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$27.29M*	-$27.51M	$223.00K*	$1.76M	-1545.95%*	(m)	-$27.82M*	(m)	$17.34M	(m)	-$30.00K
2025-06-30	Reported	-$25.88M*	-$26.23M	$355.00K*	$1.97M	-1311.56%*	(m)	-$29.90M*	(m)	$18.35M	(m)	$37.00K
2025-03-31	Reported	-$8.97M	(m)	(m)	(m)	-31.13%	(m)	-$12.37M	(m)	$18.51M	(m)	$34.00K
2024-12-31	Reported	-$35.44M	(m)	(m)	(m)	-2471.55%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$34.23M*	-$34.50M	$267.00K*	$560.00K	-6113.04%*	(m)	-$34.03M*	(m)	$19.17M	(m)	$15.00K
2024-06-30	Reported	$71.30M*	$71.10M	$194.00K*	$563.00K	12663.77%*	(m)	-$63.90M	(m)	$20.91M	(m)	$18.00K
2024-03-31	Reported	-$37.23M	(m)	(m)	(m)	(m)	(m)	-$33.60M	(m)	$19.85M	(m)	$19.00K
2023-12-31	Reported	-$25.14M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$27.11M*	-$27.21M	$104.00K*	(m)	(m)	(m)	-$68.80M	(m)	$19.08M	(m)	$26.00K
2023-06-30	Reported	-$25.68M*	-$25.80M	$126.00K*	(m)	(m)	(m)	-$47.90M	(m)	$15.60M	(m)	$15.00K
2023-03-31	Reported	-$29.18M	(m)	(m)	(m)	(m)	(m)	-$26.51M	(m)	$22.06M	(m)	$4.00K
2022-12-31	Reported	-$25.45M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$20.03M*	-$20.15M	$124.00K*	(m)	(m)	(m)	-$19.31M*	(m)	$14.11M	(m)	-$13.00K
2022-06-30	Reported	-$20.44M*	-$20.57M	$132.00K*	(m)	(m)	(m)	-$18.47M*	(m)	$13.82M	(m)	$4.00K
2022-03-31	Reported	-$21.14M	(m)	(m)	(m)	(m)	(m)	-$20.23M	(m)	$14.11M	(m)	$23.00K
2021-12-31	Reported	-$28.92M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$18.99M*	-$19.12M	$132.00K*	$0.00	(m)	(m)	-$14.21M*	(m)	$13.19M	(m)	$2.00K
2021-06-30	Reported	-$18.87M*	-$19.00M	$129.00K*	$0.00	(m)	(m)	-$19.20M*	(m)	$13.19M	(m)	$6.00K
2021-03-31	Reported	-$17.83M	(m)	(m)	(m)	(m)	(m)	-$18.44M	(m)	$12.10M	(m)	$6.00K
2020-12-31	Reported	-$17.55M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$16.83M*	-$16.98M	$146.00K*	$0.00	(m)	(m)	-$14.33M*	(m)	$11.38M	(m)	$0.00
2020-06-30	Reported	-$14.59M*	-$14.66M	$66.00K*	$0.00	(m)	(m)	-$11.46M*	(m)	$9.34M	(m)	$0.00
2020-03-31	Reported	-$10.55M	(m)	(m)	(m)	-351.50%	(m)	-$15.53M	(m)	$8.91M	(m)	$148.00K
2019-12-31	Reported	-$10.84M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$16.95M*	-$16.98M	$27.00K*	$0.00	(m)	(m)	-$12.77M*	(m)	$8.59M	(m)	$0.00
2019-06-30	Reported	-$13.39M*	-$13.41M	$24.00K*	$0.00	(m)	(m)	-$14.29M*	(m)	$8.85M	(m)	$0.00
2019-03-31	Reported	-$10.42M	(m)	(m)	(m)	(m)	(m)	-$11.75M	(m)	$5.66M	(m)	$0.00
2018-12-31	Reported	-$8.03M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$8.52M*	-$8.54M	$26.00K*	(m)	(m)	(m)	-$6.72M*	(m)	$6.16M	(m)	(m)
2018-06-30	Reported	-$6.35M*	-$6.38M	$25.00K*	(m)	(m)	(m)	-$5.78M*	(m)	$4.75M	(m)	(m)
2018-03-31	Reported	-$6.08M	(m)	(m)	(m)	(m)	(m)	-$6.18M	(m)	$4.74M	(m)	(m)
2017-12-31	Reported	$2.2M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$13.00M*	-$13.06M	$52.00K*	(m)	(m)	(m)	-$5.09M*	(m)	$10.60M	(m)	(m)
2017-06-30	Reported	-$5.60M*	-$5.64M	$48.00K*	(m)	(m)	(m)	(m)	(m)	$3.91M	(m)	(m)
2017-03-31	Reported	-$5.78M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$4.39M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$85.61M	(m)	(m)	(m)	-243.80%	(m)	-$85.62M	(m)	$72.72M	(m)	$41.00K
2024-12-31	Reported	-$35.61M	(m)	(m)	(m)	-1392.45%	$326.00K	-$130.90M	(m)	$81.64M	(m)	$310.00K
2023-12-31	Reported	-$107.1M	(m)	(m)	(m)	(m)	$60.00K	-$96.51M	(m)	$72.02M	(m)	$78.00K
2022-12-31	Reported	-$87.06M	(m)	(m)	(m)	(m)	$103.00K	-$77.10M	(m)	$61.06M	(m)	$28.00K
2021-12-31	Reported	-$84.61M	(m)	(m)	(m)	(m)	(m)	-$70.91M	(m)	$50.65M	(m)	$17.00K
2020-12-31	Reported	-$59.52M	(m)	(m)	(m)	-1984.10%	(m)	-$58.82M	(m)	$41.93M	(m)	$148.00K
2019-12-31	Reported	-$51.6M	(m)	(m)	(m)	(m)	(m)	-$48.05M	(m)	$30.16M	(m)	$0.00
2018-12-31	Reported	-$28.98M	(m)	(m)	(m)	(m)	(m)	-$25.42M	(m)	$20.35M	(m)	$0.00
2017-12-31	Reported	-$22.18M	(m)	(m)	(m)	(m)	(m)	-$21.31M	(m)	$17.07M	(m)	(m)
2016-12-31	Reported	-$24.06M	(m)	(m)	(m)	(m)	(m)	-$21.64M	(m)	$17.83M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Inhibikase Therapeutics, Inc. (IKT)	United States	$0.296B	-4.44
SAB Biotherapeutics, Inc. (SABS)	United States	$0.306B	-25.49
Century Therapeutics, Inc. (IPSC)	United States	$0.306B	-4.02
Liminatus Pharma, Inc. (LIMN)	United States	$0.282B
FATE THERAPEUTICS INC (FATE)	United States	$0.280B	-2.51
Lexeo Therapeutics, Inc. (LXEO)	United States	$0.278B	-4.19
PALISADE BIO, INC. (PALI)	United States	$0.275B	-11.41
Invivyd, Inc. (IVVD)	United States	$0.270B	-2.42
SUTRO BIOPHARMA, INC. (STRO)	United States	$0.260B	-3.05
Ocugen, Inc. (OCGN)	United States	$0.343B	-6.34